P53 Over Expression in Bladder Carcinoma

Abstract

Objective: The purpose of this research was to find out how prevalent p53 overexpression is in bladder urothelial cancer.

Methodology: This descriptive, cross-sectional study was conducted in KRL Hospital Islamabad from April 2018 to October 2018. All patients with biopsy-proven urinary bladder cancer, irrespective of gender or age range, were included in the research. Non-probability, consecutive sampling technique was used.  The immunohistochemical processing was completed, and the results for p53 expression (positive/negative) were interpreted by the consultant pathologist. SPSS version 22.0 was used for the statistical analysis. Quantitative information, such as the patient's age and length of illness, were displayed using the mean and standard deviation. The P value was less than 0.05, the result was declared significant.

Results: The participants in this study ranged in age from 15 to 70 years old, with a mean age of 47.39 ± 10.26 years. The male to female ratio was 1.6:1 among these 74 patients, with 45 (60.81 percent) being male and 29 (39.19 percent) being female. Overexpression of p53 was found in 31 (41.89 percent) of bladder urothelial carcinoma cases.

Conclusion: This study concluded that the frequency of p53 overexpression in bladder urothelial carcinoma is very high.